TacticScaleWhat Revvity Does & How It Makes Money (RVTY)
Updated October 2026 · reflects Revvity's latest reported financials
Life science tools and diagnostics company for labs and disease screening. It makes money selling instruments and then recurring sales of reagents, consumables, software subscriptions, service contracts and extended warranties to pharma, biotech, clinical labs, research institutions and public health agencies.
How Revvity makes money
It makes money selling instruments and then recurring sales of reagents, consumables, software subscriptions, service contracts and extended warranties to pharma, biotech, clinical labs, research institutions and public health agencies.
What Revvity does
Revvity, Inc., known as PerkinElmer until April 2023, is a Waltham, Massachusetts-based health sciences company founded in 1937. It serves two broad markets. In life sciences, it supplies instruments, reagents, detection and imaging technologies, and software such as ChemDraw, BioLegend and Dharmacon to pharmaceutical and biotech companies and academic labs for drug discovery and genomic workflows, including next-generation sequencing. In diagnostics, Revvity provides assay platforms and reagents for early detection of conditions in pregnancy and early childhood, such as Down syndrome, hypothyroidism, muscular dystrophy and metabolic disorders. It also offers infectious disease and immunodiagnostic testing through brands like EUROIMMUN, T-SPOT and IDS. Its revenue comes from selling instruments along with recurring sales of reagents, software subscriptions and services.
Products & services
- EUROIMMUN immunodiagnostics
- NeoBase / EONIS newborn screening
- T-SPOT infectious disease testing
- BioLegend antibodies & reagents
- AlphaLISA / DELFIA detection assays
- ChemDraw scientific software
What is Revvity worth?
On an owner-earnings DCF, Revvity's most-likely value is about $113 versus a recent price near $154 (26% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$58) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Bio-Rad Laboratories (BIO) · Repligen (RGEN) · Avantor (AVTR) · Thermo Fisher Scientific (TMO) · Bio-Techne (TECH)